welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy

key information

study id #: NCT01099761

condition: Duchenne Muscular Dystrophy

status: terminated


The purpose of this study is to determine if ACE-031 is safe and well-tolerated in boys with Duchenne Muscular Dystrophy (DMD) and to select the optimal doses of ACE-031 in terms of safety and pharmacodynamic (PD) activity for designing future studies. [Note: This study was terminated based on safety data]

intervention: ACE-031 0.5 mg/kg q4wk, ACE-031 1.0 mg/kg q2wk, Placebo

mechanism of action: Myostatin inhibitor to promote muscle growth

results: https://clinicaltrials.gov/ct2/show/results/NCT01099761

last updated: November 22, 2018